<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foutadakis, S.</style></author><author><style face="normal" font="default" size="100%">Avgeris, M.</style></author><author><style face="normal" font="default" size="100%">Tokas, T.</style></author><author><style face="normal" font="default" size="100%">Stravodimos, K.</style></author><author><style face="normal" font="default" size="100%">Scorilas, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors</style></title><secondary-title><style face="normal" font="default" size="100%">Urological Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Bladder cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Bladder cancer recurrence</style></keyword><keyword><style  face="normal" font="default" size="100%">Bladder cancer relapse</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">High-grade TaT1 bladder tumors</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Kaplan-Meier Estimate</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Multivariate Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Muscle Proteins/*genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Grading</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Recurrence, Local</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Staging</style></keyword><keyword><style  face="normal" font="default" size="100%">Non-muscle invasive bladder cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Outcome Assessment, Health Care/methods/statistics &amp; numerical data</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Proto-Oncogene Proteins c-bcl-2/*genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style  face="normal" font="default" size="100%">TaT1 bladder cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Urinary Bladder Neoplasms/*genetics/pathology/*surgery</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">32</style></volume><pages><style face="normal" font="default" size="100%">39 e29-36</style></pages><isbn><style face="normal" font="default" size="100%">1873-2496 (Electronic)1078-1439 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">OBJECTIVES: More than half of the diagnosed patients with bladder cancer (BCa) recur at least once following their initial treatment. Thus, patients' monitoring and prognosis is of utmost importance. However, the need for intensive surveillance of BCa significantly burdens patients' health-related quality of life. The aim of the present study is the expression analysis of BCL2L12, a recently identified member of the BCL2 apoptosis-related gene family, in BCa and the evaluation of BCL2L12 prognostic significance for the survival outcome of the patients. METHODS AND MATERIALS: Our study included 115 patients with BCa, and tissue specimens were obtained from the tumor area as well as from adjacent normal bladder wall. BCL2L12 expression was determined using quantitative real-time polymerase chain reaction assay, and was further correlated with patients' clinicopathological features and follow-up survival data. RESULTS: Up-regulated BCL2L12 expression levels were detected in malignant bladder specimens compared with normal ones. The higher BCL2L12 expression was further associated with shorter disease-free survival of the patients with BCa. Focusing on patients with TaT1 non-muscle invasive BCa, BCL2L12 expression levels were correlated with higher recurrence rate at the first follow-up cystoscopy and were unveiled to be an independent unfavorable predictor of patients' short-term recurrence following transurethral resection. Finally, BCL2L12 expression levels were also associated with poor disease-free survival of the high-grade TaT1 patients. CONCLUSIONS: Our data highlight the unfavorable prognostic value of BCL2L12 for patients with BCa and support its potential clinical use for the assessment of TaT1 patients' recurrence risk.</style></abstract><accession-num><style face="normal" font="default" size="100%">23790536</style></accession-num><notes><style face="normal" font="default" size="100%">Foutadakis, SpyrosAvgeris, MargaritisTokas, TheodorosStravodimos, KonstantinosScorilas, AndreasengResearch Support, Non-U.S. Gov't2013/06/25 06:00Urol Oncol. 2014 Jan;32(1):39.e29-36. doi: 10.1016/j.urolonc.2013.04.005. Epub 2013 Jun 18.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece.First Department of Urology, &quot;Laiko&quot; General Hospital, Medical School, University of Athens, Athens, Greece.Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece. Electronic address: ascorilas@biol.uoa.gr.</style></auth-address></record></records></xml>